Peptides: Legal and Regulatory Risks 503A Compounding Pharmacies Must Understand Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More FDA Schedules July 2026 PCAC Review of BPC 157, TB 500, MOTs C, KPV, Semax, Epitalon, DSIP PeptideRundown Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law